Congenital generalized lipodystrophies - New insights into metabolic dysfunction

Nature Reviews Endocrinology

Volumn 11, Issue 9, 2015, Pages 522-534

  Patni, Nivedita ^a   Garg, Abhimanyu ^b  

^a Center for Human Nutrition   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACYL SN GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE BETA; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; METRELEPTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACANTHOSIS NIGRICANS; ADIPOCYTE; ADIPOSE TISSUE; ADULT; CASE REPORT; CAVEOLA; CONGENITAL GENERALIZED LIPODYSTROPHY; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DRUG POTENCY; END STAGE RENAL DISEASE; ESTHETIC SURGERY; FATTY LIVER; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; HEPATOSPLENOMEGALY; HUMAN; HYPERTRIGLYCERIDEMIA; LOW FAT DIET; MENSTRUAL IRREGULARITY; NONHUMAN; ONCOGENE C FOS; PHYSICAL ACTIVITY; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SUBSTITUTION THERAPY; GENETICS; LIPODYSTROPHY, CONGENITAL GENERALIZED; METABOLISM;

ADIPOSE TISSUE; HUMANS; LIPODYSTROPHY, CONGENITAL GENERALIZED;

EID: 84939569115     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.123     Document Type: Review

References (166)

1. Garg, A. Acquired and inherited lipodystrophies. N. Engl. J. Med. 350, 1220-1234 (2004
2. Berardinelli, W. An undiagnosed endocrinometabolic syndrome: report of 2 cases. J. Clin. Endocrinol. Metab. 14, 193-204 (1954
3. Seip, M. Lipodystrophy and gigantism with associated endocrine manifestations: a new diencephalic syndrome? Acta Paediatrica. 48, 555-574 (1959
4. Wiedemann, H. R. Newly recognized congenital progeroid disorder. Am. J. Med. Genet. 42, 857 (1992
5. Rautenstrauch, T., Snigula, F., & Wiedemann, H. R. Neonatal progeroid syndrome (Wiedemann-Rautenstrauch). A follow-up study [German]. Klin. Padiatr. 206, 440-443 (1994
6. Dunnigan, M. G., Cochrane, M. A., Kelly, A., & Scott, J. W. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q. J. Med. 43, 33-48 (1974
7. Young, L. W., et al. New syndrome manifested by mandibular hypoplasia, acroosteolysis, stiff joints and cutaneous atrophy (mandibuloacral dysplasia) in two unrelated boys. Birth Defects Orig. Artic. Ser. 7, 291-297 (1971
8. Eriksson, M., et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 423, 293-298 (2003
9. De Sandre-Giovannoli, A., et al. Lamin A truncation in Hutchinson-Gilford progeria. Science. 300, 2055 (2003
10. Garg, A., et al. Atypical progeroid syndrome due to heterozygous missense LMNA mutations. J. Clin. Endocrinol. Metab. 94, 4971-4983 (2009
11. Pelosini, C., et al. Identification of a novel mutation in the polymerase delta 1 (POLD1) gene in a lipodystrophic patient affected by mandibular hypoplasia, deafness, progeroid features (MDPL) syndrome. Metabolism. 63, 1385-1389 (2014
12. Capeau, J., et al. Human lipodystrophies: genetic and acquired diseases of adipose tissue. Endocr. Dev. 19, 1-20 (2010
13. Agarwal, A. K., et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J. Clin. Endocrinol. Metab. 88, 4840-4847 (2003
14. Chan, J. L., & Oral, E. A. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr. Pract. 16, 310-323 (2010
15. Van Maldergem, L., et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J. Med. Genet. 39, 722-733 (2002
16. Thauvin-Robinet, C., et al. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am. J. Hum. Genet. 93, 141-149 (2013
17. Dyment, D. A., et al. Mutations in PIK3R1 cause SHORT syndrome. Am. J. Hum. Genet. 93, 158-166 (2013
18. Chudasama, K. K., et al. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am. J. Hum. Genet. 93, 150-157 (2013
19. Masotti, A., et al. Keppen-Lubinsky syndrome is caused by mutations in the inwardly rectifying K+ channel encoded by KCNJ6. Am. J. Hum. Genet. 96, 295-300 (2015
20. Shastry, S., et al. A novel syndrome of mandibular hypoplasia, deafness, and progeroid features associated with lipodystrophy, undescended testes, and male hypogonadism. J. Clin. Endocrinol. Metab. 95, E192-E197 (2010
21. Garg, A., & Xing, C. De novo heterozygous FBN1 mutations in the extreme C terminal region cause progeroid fibrillinopathy. Am. J. Med. Genet. A 164A, 1341-1345 (2014
22. Garg, A., et al. Whole exome sequencing identifies de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. Am. J. Med. Genet. A http://dx.doi.org/10.1002/ajmg.a.37115
23. Prokocimer, M., Barkan, R., & Gruenbaum, Y. Hutchinson-Gilford progeria syndrome through the lens of transcription. Aging Cell. 12, 533-543 (2013
24. Ahmad, Z., Zackai, E., Medne, L., & Garg, A. Early onset mandibuloacral dysplasia due to compound heterozygous mutations in ZMPSTE24. Am. J. Med. Genet. A 152A, 2703-2710 (2010
25. Simha, V., Agarwal, A. K., Oral, E. A., Fryns, J. P., & Garg, A. Genetic and phenotypic heterogeneity in patients with mandibuloacral dysplasia-Associated lipodystrophy. J. Clin. Endocrinol. Metab. 88, 2821-2824 (2003
26. Agarwal, A. K., et al. PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am. J. Hum. Genet. 87, 866-872 (2010
27. Farhan, S. M., et al. A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset familial partial lipodystrophy. Can. J. Cardiol. 30, 1649-1654 (2014
28. Saha, B., et al. A novel LMNA mutation causes altered nuclear morphology and symptoms of familial partial lipodystrophy (Dunnigan variety) with progeroid features. Mol. Syndromol. 1, 127-132 (2010
29. Donadille, B., et al. Partial lipodystrophy with severe insulin resistance and adult progeria Werner syndrome. Orphanet J. Rare Dis. 8, 106 (2013
30. Payne, F., et al. Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. Proc. Natl Acad. Sci. USA. 111, 8901-8906 (2014
31. Garg, A. Lipodystrophies. Am. J. Med. 108, 143-152 (2000
32. Garg, A. Clinical review: Lipodystrophies: genetic and acquired body fat disorders. J. Clin. Endocrinol. Metab. 96, 3313-3325 (2011
33. Nolis, T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J. Hum. Genet. 59, 16-23 (2014
34. Pardini, V. C., et al. Leptin levels, β-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatrophic diabetes. J. Clin. Endocrinol. Metab. 83, 503-508 (1998
35. Magre, J., et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat. Genet. 28, 365-370 (2001
36. Agarwal, A. K., et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat. Genet. 31, 21-23 (2002
37. Kim, C. A., et al. Association of a homozygous nonsense caveolin 1 mutation with Berardinelli-Seip congenital lipodystrophy. J. Clin. Endocrinol. Metab. 93, 1129-1134 (2008
38. Hayashi, Y. K., et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J. Clin. Invest. 119, 2623-2633 (2009
39. Dyment, D. A., et al. Biallelic mutations at PPARG cause a congenital, generalized lipodystrophy similar to the Berardinelli-Seip syndrome. Eur. J. Med. Genet. 57, 524-526 (2014
40. Knebel, B., et al. A mutation in the c fos gene associated with congenital generalized lipodystrophy. Orphanet J. Rare Dis. 8, 119 (2013
41. Seip, M., & Trygstad, O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatrica Suppl. 413, 2-28 (1996
42. Westvik, J. Radiological features in generalized lipodystrophy. Acta Paediatrica Suppl. 413, 44-51 (1996
43. Garg, A., Fleckenstein, J. L., Peshock, R. M., & Grundy, S. M. Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J. Clin. Endocrinol. Metab. 75, 358-361 (1992
44. Seip, M., & Trygstad, O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr. Suppl. 413, 2-28 (1996
45. Garg, A., et al. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J. Clin. Endocrinol. Metab. 84, 3390-3394 (1999
46. [No authors listed]. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-1975. N. Engl. J. Med. 292, 35-41 (1975
47. Chandalia, M., Garg, A., Vuitch, F., & Nizzi, F. Postmortem findings in congenital generalized lipodystrophy. J. Clin. Endocrinol. Metab. 80, 3077-3081 (1995
48. Javor, E. D., et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J. Clin. Endocrinol. Metab. 89, 3199-3207 (2004
49. Upreti, V., Dhull, P., Patnaik, S. K., & Kumar, K. V. An unusual cause of delayed puberty: Berardinelli-Seip syndrome. J. Pediatr. Endocrinol. Metab. 25, 1157-1160 (2012
50. Musso, C., et al. The long-Term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism. 54, 255-263 (2005
51. Lungu, A. O., Zadeh, E. S., Goodling, A., Cochran, E., & Gorden, P. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 97, 563-567 (2012
52. Abel, B. S., Muniyappa, R., Skarulis, M. C., Gorden, P., & Brown, R. J. Recombinant human leptin (metreleptin) administration augments nocturnal LH secretion in lipodystrophy patients. Presented at The Endocrine Society's 97th Annual Meeting & Expo (2015
53. Maguire, M., Lungu, A., Gorden, P., Cochran, E., & Stratton, P. Pregnancy in a woman with congenital generalized lipodystrophy: leptin's vital role in reproduction. Obstet. Gynecol. 119, 452-455 (2012
54. McNally, M., et al. Successful renal transplantation in a patient with congenital generalized lipodystrophy: a case report.Am. J. Transplant. 4, 447-449 (2004
55. Miranda, D. M., et al. Novel mutations of the BSCL2 and AGPAT2 genes in 10 families with Berardinelli-Seip congenital generalized lipodystrophy syndrome. Clin. Endocrinol. (Oxf.) 71, 512-517 (2009
56. Gomes, K. B., et al. Mutations in the Seipin and AGPAT2 genes clustering in consanguineous families with Berardinelli-Seip congenital lipodystrophy from two separate geographical regions of Brazil. J. Clin. Endocrinol. Metab. 89, 357-361 (2004
57. Jiang, M., et al. Lack of testicular seipin causes teratozoospermia syndrome in men. Proc. Natl Acad. Sci. USA. 111, 7054-7059 (2014
58. Brunzell, J. D., Shankle, S. W., & Bethune, J. E. Congenital generalized lipodystrophy accompanied by cystic angiomatosis. Ann. Intern. Med. 69, 501-516 (1968
59. Fleckenstein, J. L., Garg, A., Bonte, F. J., Vuitch, M. F., & Peshock, R. M. The skeleton in congenital, generalized lipodystrophy: evaluation using whole-body radiographic surveys, magnetic resonance imaging and technetium 99m bone scintigraphy. Skeletal Radiol. 21, 381-386 (1992
60. Guell-Gonzalez, J. R., et al. Bone lesions in congenital generalised lipodystrophy. Lancet. 2, 104-105 (1971
61. Shinya, T., et al. Computed tomography findings of congenital generalized lipodystrophy: multiple nodular fatty liver and diffuse sclerosis of bones. Radiat. Med. 25, 484-487 (2007
62. Shirwalkar, H. U., et al. Congenital generalized lipodystrophy in an Indian patient with a novel mutation in BSCL2 gene. J. Inherit Metab. Dis. 31(Suppl. 2), S317-S322 (2008
63. Christensen, J. D., et al. Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J. Clin. Endocrinol. Metab. 99, E1493-E1500 (2014
64. Garg, A., Chandalia, M., & Vuitch, F. Severe islet amyloidosis in congenital generalized lipodystrophy. Diabetes Care. 19, 28-31 (1996
65. Oral, E. A., et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570-578 (2002
66. Diker-Cohen, T., Cochran, E., Gorden, P., & Brown, R. J. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J. Clin. Endocrinol. Metab. 100, 1802-1810 (2015
67. Garg, A. in Dyslipidemias: Pathophysiology, Evaluation and Management. (ed. Garg, A.) 287-302 (Springer, 2015
68. Rego, A. G., et al. Cardiometabolic abnormalities in patients with Berardinelli-Seip syndrome [Portuguese]. Arq. Bras. Cardiol. 94, 109-118 (2010
69. Indumathi, C. K., Lewin, S., & Ayyar, V. Berardinelli Seip syndrome with insulin-resistant diabetes mellitus and stroke in an infant. Indian J. Endocrinol. Metab. 15, S62-S64 (2011
70. Haque, W. A., Shimomura, I., Matsuzawa, Y., & Garg, A. Serum adiponectin and leptin levels in patients with lipodystrophies. J. Clin. Endocrinol. Metab. 87, 2395-2398 (2002
71. Antuna-Puente, B., et al. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1 acylglycerol 3 phosphate O acyltransferase 2 deficiency. J. Clin. Endocrinol. Metab. 95, 1463-1468 (2010
72. McDuffie, J. R., et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J. Clin. Endocrinol. Metab. 89, 4258-4263 (2004
73. Rajab, A., et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 6, e1000874 (2010
74. Shastry, S., et al. Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. Am. J. Med. Genet. A 152A, 2245-2253 (2010
75. Ardissone, A., et al. Novel PTRF mutation in a child with mild myopathy and very mild congenital lipodystrophy. BMC Med. Genet. 14, 89 (2013
76. Dwianingsih, E. K., et al. A Japanese child with asymptomatic elevation of serum creatine kinase shows PTRF-CAVIN mutation matching with congenital generalized lipodystrophy type 4. Mol. Genet. Metab. 101, 233-237 (2010
77. UniProt. FOS -FOS Protein -Homo sapiens (human) [online], http://www.uniprot.org/uniprot/Q6FG41 (2015
78. Online Mendelian Inheritance in Man©. #608594 Lipodystrophy, congenital generalized, type 1; CGL1 [online], http://omim.org/entry/608594 (2014
79. Garg, A., & Agarwal, A. K. Lipodystrophies: disorders of adipose tissue biology. Biochim. Biophys. Acta. 1791, 507-513 (2009
80. Cortes, V. A., et al. Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab. 9, 165-176 (2009
81. Agarwal, A. K., & Garg, A. Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways. Trends Endocrinol. Metab. 14, 214-221 (2003
82. Takeuchi, K., & Reue, K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. Am. J. Physiol. Endocrinol. Metab. 296, E1195-E1209 (2009
83. Leung, D. W. The structure and functions of human lysophosphatidic acid acyltransferases. Front. Biosci. 6, D944-D953 (2001
84. Agarwal, A. K., Barnes, R. I., & Garg, A. Genetic basis of congenital generalized lipodystrophy. Int. J. Obes. Relat. Metab. Disord. 28, 336-339 (2004
85. Agarwal, A. K., & Garg, A. Enzymatic activity of the human 1 acylglycerol 3 phosphate O-Acyltransferase isoform 11: upregulated in breast and cervical cancers. J. Lipid Res. 51, 2143-2152 (2010
86. Agarwal, A. K. Lysophospholipid acyltransferases: 1 acylglycerol 3-phosphate O acyltransferases. From discovery to disease. Curr. Opin. Lipidol. 23, 290-302 (2012
87. Fu, M., et al. Mutations in Gng3lg and AGPAT2 in Berardinelli-Seip congenital lipodystrophy and Brunzell syndrome: phenotype variability suggests important modifier effects. J. Clin. Endocrinol. Metab. 89, 2916-2922 (2004
88. Magre, J., et al. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes. 52, 1573-1578 (2003
89. Haque, W., Garg, A., & Agarwal, A. K. Enzymatic activity of naturally occurring 1 acylglycerol 3 phosphate O-Acyltransferase 2 mutants associated with congenital generalized lipodystrophy. Biochem. Biophys. Res. Commun. 327, 446-453 (2005
90. Simha, V., & Garg, A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy due to mutations in the AGPAT2 or Seipin genes. J. Clin. Endocrinol. Metab. 88, 5433-5437 (2003
91. Gale, S. E., et al. A regulatory role for 1 acylglycerol 3 phosphate O-Acyltransferase 2 in adipocyte differentiation. J. Biol. Chem. 281, 11082-11089 (2006
92. Subauste, A. R., et al. Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes. 61, 2922-2931 (2012
93. Online Mendelian Inheritance in Man©. #269700 Lipodystrophy, congenital generalized, type 2; CGL2 [online], http://omim.org/entry/269700 (2014
94. Agarwal, A. K., & Garg, A. Seipin: a mysterious protein. Trends Mol. Med. 10, 440-444 (2004
95. Szymanski, K. M., et al. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proc. Natl Acad. Sci. USA. 104, 20890-20895 (2007
96. Fei, W., et al. Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast. J. Cell Biol. 180, 473-482 (2008
97. Yang, W., et al. BSCL2/seipin regulates adipogenesis through actin cytoskeleton remodelling. Hum. Mol. Genet. 23, 502-513 (2014
98. Cartwright, B. R., et al. Seipin performs dissectible functions in promoting lipid droplet biogenesis and regulating droplet morphology. Mol. Biol. Cell. 26, 726-739 (2015
99. Talukder, M. M., Sim, M. F., O'Rahilly, S., Edwardson, J. M., & Rochford, J. J. Seipin oligomers can interact directly with AGPAT2 and lipin 1, physically scaffolding critical regulators of adipogenesis. Mol. Metab. 4, 199-209 (2015
100. Sim, M. F., et al. Analysis of naturally occurring mutations in the human lipodystrophy protein seipin reveals multiple potential pathogenic mechanisms. Diabetologia. 56, 2498-2506 (2013
101. Sim, M. F., et al. The human lipodystrophy protein seipin is an ER membrane adaptor for the adipogenic PA phosphatase lipin 1. Mol. Metab. 2, 38-46 (2012
102. Wee, K., Yang, W., Sugii, S., & Han, W. Towards a mechanistic understanding of lipodystrophy and seipin functions. Biosci. Rep. 3, e00141 (2014
103. Schuster, J., et al. Exome sequencing circumvents missing clinical data and identifies a BSCL2 mutation in congenital lipodystrophy. BMC Med. Genet. 15, 71 (2014
104. Guillen-Navarro, E., et al. A new seipin-Associated neurodegenerative syndrome. J. Med. Genet. 50, 401-409 (2013
105. Windpassinger, C., et al. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat. Genet. 36, 271-276 (2004
106. Cui, X., et al. Seipin ablation in mice results in severe generalized lipodystrophy. Hum. Mol. Genet. 20, 3022-3030 (2011
107. Chen, W., et al. Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-Autonomous regulator of lipolysis essential for adipocyte differentiation. Mol. Cell Biol. 32, 1099-1111 (2012
108. Prieur, X., et al. Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice. Diabetologia. 56, 1813-1825 (2013
109. Chen, W., Zhou, H., Saha, P., Li, L., & Chan, L. Molecular mechanisms underlying fasting modulated liver insulin sensitivity and metabolism in male lipodystrophic Bscl2/Seipin-deficient mice. Endocrinology. 155, 4215-4225 (2014
110. Liu, L., et al. Adipose-specific knockout of Seipin/Bscl2 results in progressive lipodystrophy. Diabetes. 63, 2320-2331 (2014
111. Ebihara, C., et al. Seipin is necessary for normal brain development and spermatogenesis in addition to adipogenesis. Hum. Mol. Genet. 24, 4238-4249 (2015
112. Chen, W., et al. Altered lipid metabolism in residual white adipose tissues of Bscl2 deficient mice. PLoS ONE. 8, e82526 (2013
113. Boutet, E., et al. Seipin deficiency alters fatty acid ?9 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy. Biochimie. 91, 796-803 (2009
114. Online Mendelian Inheritance in Man©. #612526 Lipodystrophy, congenital generalized, type 3; CGL3 [online], http://omim.org/entry/612526 (2014
115. Engelman, J. A., Zhang, X. L., Galbiati, F., & Lisanti, M. P. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav 1, 2, and 3). Cav 1 and Cav 2 genes map to a known tumor suppressor locus (6 A2/7q31). FEBS Lett. 429, 330-336 (1998
116. Stan, R. V. Structure of caveolae. Biochim. Biophys. Acta. 1746, 334-348 (2005
117. Parton, R. G., & Simons, K. The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 8, 185-194 (2007
118. Razani, B., & Lisanti, M. P. Caveolin-deficient mice: insights into caveolar function human disease. J. Clin. Invest. 108, 1553-1561 (2001
119. Blouin, C. M., et al. Lipid droplet analysis in caveolin-deficient adipocytes: alterations in surface phospholipid composition and maturation defects. J. Lipid Res. 51, 945-956 (2010
120. Briand, N., et al. Caveolin 1 expression and cavin stability regulate caveolae dynamics in adipocyte lipid store fluctuation. Diabetes. 63, 4032-4044 (2014
121. Bosch, M., et al. Caveolin 1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility. Curr. Biol. 21, 681-686 (2011
122. Asterholm, I. W., Mundy, D. I., Weng, J., Anderson, R. G., & Scherer, P. E. Altered Mitochondrial Function and Metabolic Inflexibility Associated with Loss of Caveolin 1. Cell Metab. 15, 171-185 (2012
123. Williams, T. M., & Lisanti, M. P. Caveolin 1 in oncogenic transformation, cancer, and metastasis. Am. J. Physiol. Cell Physiol. 288, C494-C506 (2005
124. Le Lay, S., & Kurzchalia, T. V. Getting rid of caveolins: phenotypes of caveolin-deficient animals. Biochim. Biophys. Acta. 1746, 322-333 (2005
125. Drab, M., et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin 1 gene-disrupted mice. Science. 293, 2449-2452 (2001
126. Austin, E. D., et al. Whole exome sequencing to identify a novel gene (caveolin 1) associated with human pulmonary arterial hypertension. Circ. Cardiovasc. Genet. 5, 336-343 (2012
127. Online Mendelian Inheritance in Man©. #613327 Lipodystrophy, congenital generalized, type 4; CGL4 [online], http://omim.org/entry/613327 (2013
128. Liu, L., & Pilch, P. F. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J. Biol. Chem. 283, 4314-4322 (2008
129. Perez-Diaz, S., et al. Polymerase I and transcript release factor (PTRF) regulates adipocyte differentiation and determines adipose tissue expandability. FASEB J. 28, 3769-3779 (2014
130. Rajab, A., Heathcoate, K., Joshi, S., Jeffery, S., & Patton, M. Heterogeneity for congenital generalized lipodystrophy in seventeen patients from Oman. Am. J. Hum. Genet. 110, 219-225 (2002
131. Simha, V., Agarwal, A. K., Aronin, P. A., Iannaccone, S. T., & Garg, A. Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability. Am. J. Med. Genet. A 146A, 2318-2326 (2008
132. Liu, L., et al. Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metab. 8, 310-317 (2008
133. Ding, S. Y., et al. Pleiotropic effects of cavin 1 deficiency on lipid metabolism. J. Biol. Chem. 289, 8473-8483 (2014
134. GeneTests [online], http://www.genetests.org (2015
135. Cortes, V. A., et al. Divergent metabolic phenotype between two sisters with congenital generalized lipodystrophy due to double AGPAT2 homozygous mutations. A clinical, genetic and in silico study. PLoS ONE. 9, e87173 (2014
136. Agarwal, A. K., & Garg, A. Genetic basis of lipodystrophies and management of metabolic complications. Annu. Rev. Med. 57, 297-311 (2006
137. Agarwal, A. K., et al. Human 1 acylglycerol 3-phosphate O acyltransferase isoforms 1 and 2: biochemical characterization and inability to rescue hepatic steatosis in Agpat2-/- gene lipodystrophic mice. J. Biol. Chem. 286, 37676-37691 (2011
138. Sankella, S., Garg, A., Horton, J. D., & Agarwal, A. K. Hepatic gluconeogenesis is enhanced by phosphatidic acid which remains uninhibited by insulin in lipodystrophic Agpat2-/- mice. J. Biol. Chem. 289, 4762-4777 (2014
139. Petersen, K. F., et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109, 1345-1350 (2002
140. Muniyappa, R., et al. Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy. Diabetes Care. 37, 1101-1107 (2014
141. Boden, G. Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes Obes. 18, 139-143 (2011
142. Okada, E., Iwahira, Y., & Maruyama, Y. Buttock deformity repair for congenital generalized lipodystrophy. Plast. Reconstr. Surg. 95, 744-746 (1995
143. [No authors listed]. Metreleptin (Myalept): a leptin analog for generalized lipodystrophy. Med. Lett. Drugs Ther. 57, 13-14 (2015
144. Simha, V., & Garg, A. Inherited lipodystrophies and hypertriglyceridemia. Curr. Opin. Lipidol. 20, 300-308 (2009
145. Handelsman, Y., et al. The clinical approach to the detection of lipodystrophy -An AACE consensus statement. Endocr. Pract. 19, 107-116 (2013
146. Napolitano, C., & Priori, S. G. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 4, 675-678 (2007
147. Prieur, X., Le May, C., Magre, J., & Cariou, B. Congenital lipodystrophies and dyslipidemias. Curr. Atheroscler. Rep. 16, 437 (2014
148. Araujo-Vilar, D., et al. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-Term Spanish experience. Endocrine. 49, 139-147 (2014
149. Beltrand, J., et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics. 120, e291-e296 (2007
150. Chan, J. L., et al. Clinical effects of long-Term metreleptin treatment in patients with lipodystrophy. Endocr. Pract. 17, 922-932 (2011
151. Safar Zadeh, E., et al. The liver diseases of lipodystrophy: the long-Term effect of leptin treatment. J. Hepatol. 59, 131-137 (2013
152. Ebihara, K., et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J. Clin. Endocrinol. Metab. 92, 532-541 (2007
153. FDA. Endocrinologic and metabolic drugs advisory committee briefing document: METRELEPTIN (BLA STN125390) [online], http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm377929.pdf. (2013
154. Oral, E. A., & Chan, J. L. Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr. Pract. 16, 324-333 (2010
155. Cortes, V. A., et al. Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2-/- lipodystrophic mice independent of hepatocyte leptin receptors. J. Lipid Res. 55, 276-288 (2014
156. Chou, K., & Perry, C. M. Metreleptin: first global approval. Drugs. 73, 989-997 (2013
157. Barter, P. J., et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007
158. Okamoto, H., et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406, 203-207 (2000
159. Robciuc, M. R., et al. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler. Thromb. Vasc. Biol. 33, 1706-1713 (2013
160. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01529424 (2014
161. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01749878 (2015
162. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01265498 (2014
163. Neuschwander-Tetri, B. A., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 385, 956-965 (2015
164. Musso, C., et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore) 83, 209-222 (2004
165. Pivnick, E. K., et al. Neonatal progeroid (Wiedemann-Rautenstrauch) syndrome: report of five new cases and review. Am. J. Med. Genet. 90, 131-140 (2000
166. Hou, J. W. Natural course of neonatal progeroid syndrome. Pediatr. Neonatol. 50, 102-109 (2009